Get Diamond plan for FREE

    logo

    Amylyx Pharmaceuticals, Inc. (AMLX)

    Price:

    7.99 USD

    ( - -0.01 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    AMLX
    Name
    Amylyx Pharmaceuticals, Inc.
    Industry
    Biotechnology
    Sector
    Healthcare
    Price
    7.990
    Market Cap
    712.448M
    Enterprise value
    182.167M
    Currency
    USD
    Ceo
    Joshua B. Cohen
    Full Time Employees
    123
    Website
    Ipo Date
    2022-01-07
    City
    Cambridge
    Address
    43 Thorndike Street

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    Incyte Corporation

    VALUE SCORE:

    9

    Symbol
    INCY
    Market Cap
    16.973B
    Industry
    Biotechnology
    Sector
    Healthcare

    2nd position

    Genmab A/S

    VALUE SCORE:

    11

    Symbol
    GMAB
    Market Cap
    94.051B
    Industry
    Biotechnology
    Sector
    Healthcare

    The best

    Agios Pharmaceuticals, Inc.

    VALUE SCORE:

    12

    Symbol
    AGIO
    Market Cap
    2.150B
    Industry
    Biotechnology
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -3.796
    P/S
    -2.861k
    P/B
    4.242
    Debt/Equity
    0.036
    EV/FCF
    -3.986
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    -2.652k
    Earnings yield
    -0.263
    Debt/assets
    0.031
    FUNDAMENTALS
    Net debt/ebidta
    0.267
    Interest coverage
    0
    Research And Developement To Revenue
    -374.795
    Intangile to total assets
    0
    Capex to operating cash flow
    -0.000
    Capex to revenue
    -0.116
    Capex to depreciation
    0.043
    Return on tangible assets
    -0.964
    Debt to market cap
    0.008
    Piotroski Score
    2.000
    FUNDAMENTALS
    PEG
    -0.195
    P/CF
    -4.324
    P/FCF
    -4.325
    RoA %
    -96.404
    RoIC %
    -112.927
    Gross Profit Margin %
    545.783
    Quick Ratio
    8.723
    Current Ratio
    8.723
    Net Profit Margin %
    75.341k
    Net-Net
    1.731
    FUNDAMENTALS PER SHARE
    FCF per share
    -1.859
    Revenue per share
    -0.003
    Net income per share
    -2.105
    Operating cash flow per share
    -1.858
    Free cash flow per share
    -1.859
    Cash per share
    2.029
    Book value per share
    1.883
    Tangible book value per share
    1.883
    Shareholders equity per share
    1.883
    Interest debt per share
    0.067
    TECHNICAL
    52 weeks high
    8.720
    52 weeks low
    2.045
    Current trading session High
    8.180
    Current trading session Low
    7.860
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.629
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -7.324
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.142
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -2.409

    No data to display

    logo

    Country
    GB
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -5.784
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.492
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -7.037
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.207
    DESCRIPTION

    Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

    NEWS
    https://images.financialmodelingprep.com/news/amylyx-pharmaceuticals-inc-amlx-q2-2025-earnings-call-transcript-20250807.jpg
    Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2025 Earnings Call Transcript

    seekingalpha.com

    2025-08-07 22:35:28

    Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Camille L. Bedrosian - Chief Medical Officer James M.

    https://images.financialmodelingprep.com/news/amylyx-amlx-q2-net-loss-narrows-43-20250807.jpg
    Amylyx (AMLX) Q2 Net Loss Narrows 43%

    fool.com

    2025-08-07 11:13:46

    Amylyx (AMLX) Q2 Net Loss Narrows 43%

    https://images.financialmodelingprep.com/news/amylyx-pharmaceuticals-reports-second-quarter-2025-financial-results-20250807.jpg
    Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

    businesswire.com

    2025-08-07 07:00:00

    CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results.

    https://images.financialmodelingprep.com/news/amylyx-pharmaceuticals-to-report-second-quarter-2025-financial-results-20250731.jpg
    Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

    businesswire.com

    2025-07-31 09:00:00

    CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025.

    https://images.financialmodelingprep.com/news/amylyx-pharmaceuticals-a-highrisk-pipeline-with-strong-upside-potential-20250721.jpg
    Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential

    seekingalpha.com

    2025-07-21 16:26:19

    Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential

    https://images.financialmodelingprep.com/news/amylyx-alert-bragar-eagel-squire-pc-is-investigating-amylyx-20250714.jpg
    AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

    globenewswire.com

    2025-07-14 18:26:00

    Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Amylyx (AMLX) To Contact Him Directly To Discuss Their Options

    https://images.financialmodelingprep.com/news/amylyx-drug-slashes-sugar-spikes-postweight-loss-surgery-20250714.jpg
    Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery

    benzinga.com

    2025-07-14 14:15:11

    Amylyx Pharmaceuticals, Inc. AMLX on Sunday presented new exploratory analyses from its Phase 2 PREVENT and Phase 2b trials of avexitide—an investigational GLP-1 receptor antagonist—at the Endocrine Society's annual meeting (ENDO 2025).

    https://images.financialmodelingprep.com/news/amylyx-pharmaceuticals-presents-new-exploratory-analyses-from-phase-2-20250713.jpg
    Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025

    businesswire.com

    2025-07-13 17:00:00

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the presentation of new exploratory analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist for the treatment of post-bariatric hypoglycemia (PBH) at the Endocrine Society's annual meeting (ENDO 2025). In the Phase 2b trial, avexitide 90 mg once daily, the dose being.

    https://images.financialmodelingprep.com/news/amylyx-pharmaceuticals-to-host-event-to-discuss-postbariatric-hypoglycemia-20250708.jpg
    Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025

    businesswire.com

    2025-07-08 07:00:00

    CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025.

    https://images.financialmodelingprep.com/news/amylyx-alert-bragar-eagel-squire-pc-is-investigating-amylyx-20250707.jpg
    AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

    globenewswire.com

    2025-07-07 21:00:00

    NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) on behalf of long-term stockholders following a class action complaint that was filed against Amylyx on July 1, 2025 with a Class Period from November 11, 2022 to November 8, 2023. Our investigation concerns whether the board of directors of Amylyx have breached their fiduciary duties to the company.

    https://images.financialmodelingprep.com/news/why-shares-in-amylyx-pharmaceuticals-soared-this-week-20250627.jpg
    Why Shares in Amylyx Pharmaceuticals Soared This Week

    fool.com

    2025-06-27 07:56:58

    Shares in Amylyx Pharmaceuticals (AMLX 3.83%) were up almost 28% in the week to Friday morning. The move comes after an analyst at Guggenheim initiated coverage of the small-cap stock and issued a buy recommendation, accompanied by a price target of $17.

    https://images.financialmodelingprep.com/news/amylyx-eyes-2b-opportunity-in-postsurgery-sugar-crash-market-20250624.jpg
    Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market

    benzinga.com

    2025-06-24 14:59:09

    Guggenheim Partners on Monday initiated coverage on Amylyx Pharmaceuticals, Inc. AMLX, noting the company is poised to open post-bariatric hypoglycemia's (PBH) blockbuster potential.

    https://images.financialmodelingprep.com/news/amylyx-pharmaceuticals-inc-amlx-investigation-bronstein-gewirtz-grossman-llc-20250617.jpg
    Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

    accessnewswire.com

    2025-06-17 10:00:00

    NEW YORK CITY, NY / ACCESS Newswire / June 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.

    https://images.financialmodelingprep.com/news/bronstein-gewirtz-grossman-llc-announces-an-investigation-against-amylyx-20250615.jpg
    Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation

    accessnewswire.com

    2025-06-15 10:00:00

    NEW YORK CITY, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.

    https://images.financialmodelingprep.com/news/bronstein-gewirtz-grossman-llc-encourages-amylyx-pharmaceuticals-inc-amlx-20250612.jpg
    Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation

    accessnewswire.com

    2025-06-12 10:00:00

    NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amylyx Pharmaceuticals, Inc. ("Amylyx" or "the Company") (NASDAQ:AMLX). Investors who purchased Amylyx securities prior to November 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/AMLX.

    https://images.financialmodelingprep.com/news/kuehn-law-encourages-investors-of-amylyx-pharmaceuticals-inc-to-20250611.jpg
    Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

    globenewswire.com

    2025-06-11 10:08:00

    NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciary duties to shareholders.